Menu
ÚHKT

doc. Mgr. Kateřina Machová Poláková, Ph.D.

vedoucí oddělení molekulární genetiky

Tel: +420 221 977 305
Email: Katerina.Machova@uhkt.cz

Impaktované publikace

[1]

Cross, N.C.; White, H.E.; Colomer, D.; Ehrencrona, H.; Foroni, L.; Gottardi, E.; Lange, T.; Lion, T.; Machova Polakova, K.; Dulucq, S.; Martinelli, G.; Oppliger Leibundgut, E.; Pallisgaard, N.; Barbany, G.; Sacha, T.; Talmaci, R.; Izzo, B.; Saglio, G.; Pane, F.; Müller, M.C.; Hochhaus, A.

Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia

[rok vydání 2015, impact factor 12.104 ]

[2]

White, H.; Deprez, L.; Corbisier, P.; Hall, V.; Lin, F.; Mazoua, S.; Trapmann, S.; Aggerholm, A.; Andrikovics, H.; Akiki, S.; Barbany, G.; Boeckx, N.; Bench, A.; Catherwood, M.; Cayuela, J.-M.; Chudleigh, S.; Clench, T.; Colomer, D.; Daraio, F.; Dulucq, S.; Farrugia, J.; Fletcher, L.; Foroni, L.; Ganderton, R.; Gerrard, G.; Gineikiene, E.; Hayette, S.; El Housni, H.; Izzo, B.; Jansson, M.; Johnels, P.; Jurcek, T.; Kairisto, V.; Kizilors, A.; Kim, D.-W.; Lange, T.; Lion, T.; Polakova, K.M.; Martinelli, G.; McCarron, S.; Merle, P.A.; Milner, B.; Mitterbauer-Hohendanner, G.; Nagar, M.; Nickless, G.; Nomdedeu, J.; Nymoen, D.A.; Leibundgut, E.O.; Ozbek, U.; Pajic, T.; Pfeifer, H.; Preudhomme, C.; Raudsepp, K.; Romeo, G.; Sacha, T.; Talmaci, R.; Touloumenidou, T.; Van der Velden, V.H.J.; Waits, P.; Wang, L.; Wilkinson, E.; Wilson, G.; Wren, D.; Zadro, R.; Ziermann, J.; Zoi, K.; Muller, M.C.; Hochhaus, A.; Schimmel, H.; Cross, N.C.P.; Emons, H.

A certified plasmid reference material for the standardisation of BCR-ABL1 mRNA quantification by real-time quantitative PCR

[rok vydání 2014, impact factor 12.104 ]

[3]

Soverini, S.; De Benedittis, C.; Papayannidis, C.; Polakova, K.M.; Venturi, C.; Russo, D.; Bresciani, P.; Iurlo, A.; Mancini, M.; Vitale, A.; Chiaretti, S.; Foa, R.; Abruzzese, E.; Sora, F.; Kohlmann, A.; Haferlach, T.; Baccarani, M.; Cavo, M.; Martinelli, G.

Clinical impact of low-burden BCR-ABL1 mutations detectable by amplicon deep sequencing in Philadelphia-positive acute lymphoblastic leukemia patients

[rok vydání 2016, impact factor 12.104 ]

[4]

Kramarzova, K.; Stuchly, J.; Willasch, A.; Gruhn, B.; Schwarz, J.; Cermak, J.; Machova-Polakova, K.; Fuchs, O.; Stary, J.; Trka, J.; Boublikova, L.

Real-time PCR quantification of major Wilms' tumor gene 1 (WT1) isoforms in acute myeloid leukemia, their characteristic expression patterns and possible functional consequences

[rok vydání 2012, impact factor 10.164 ]

[5]

Soverini, S.; De Benedittis, C.; Machova Polakova, K.; Brouckova, A.; Horner, D.; Iacono, M.; Castagnetti, F.; Gugliotta, G.; Palandri, F.; Papayannidis, C.; Iacobucci, I.; Venturi, C.; Bochicchio, M.T.; Klamova, H.; Cattina, F.; Russo, D.; Bresciani, P.; Binotto, G.; Giannini, B.; Kohlmann, A.; Haferlach, T.; Roller, A.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.

Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultra-deep sequencing of the BCR-ABL kinase domain

[rok vydání 2013, impact factor 9.775 ]

[6]

Linhartova, J.; Hovorkova, L.; Soverini, S.; Benesova, A.; Jaruskova, M.; Klamova, H.; Zuna, J.; Machova Polakova, K.

Characterization of 46 patient-specific BCR-ABL1 fusions and detection of SNPs upstream and downstream the breakpoints in chronic myeloid leukemia using next generation sequencing

[rok vydání 2015, impact factor 5.888 ]

[7]

Soverini, S.; De Benedittis, C.; Machova Polakova, K.; Linhartova, J.; Castagnetti, F.; Gugliotta, G.; Papayannidis, C.; Mancini, M.; Klamova, H.; Salvucci, M.; Crugnola, M.; Iurlo, A.; Albano, F.; Russo, D.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

[rok vydání 2016, impact factor 5.008 ]

[8]

Zackova, D.; Klamova, H.; Dusek, L.; Muzik, J.; Machová Polakova, K.; Moravcova, J.; Jurcek, T.; Dvorakova, D.; Racil, Z.; Pospisil, Z.; Oltova, A.; Michalova, K.; Brezinova, J.; Razga, F.; Doubek, M.; Cetkovsky, P.; Trneny, M.; Mayer, J.

Imatinib as the first line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?

[rok vydání 2010, impact factor 4.671 ]

[9]

Machová Poláková, K.; Lopotová, T.; Klamová, H.; Burda, P.; Trněný, M.; Stopka, T.; Moravcová, J.

Expression patterns of microRNAs associated with CML phases and their disease related targets

[rok vydání 2011, impact factor 3.993 ]

[10]

Pavlik, T.; Janousova, E.; Mayer, J.; Indrak, K.; Jarosova, M.; Klamova, H.; Zackova, D.; Voglova, J.; Faber, E.; Karas, M.; Machova Polakova, K.; Racil, Z.; Demeckova, E.; Demitrovicova, L.; Tothova, E.; Chudej, J.; Markuljak, I.; Cmunt, E.; Kozak, T.; Muzik, J.; Dusek, L.

Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications

[rok vydání 2013, impact factor 3.477 ]

[11]

Soverini, S.; De Benedittis, C.; Castagnetti F.; Gugliotta, G.; Mancini, M.; Bavaro, L.; Machova Polakova, K.; Linhartova, J.; Iurlo, A.; Russo, D.; Pane, F.; Saglio, G.; Rosti, G.; Cavo, M.; Baccarani, M.; Martinelli, G.

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

[rok vydání 2016, impact factor 3.265 ]

[12]

Preuner, S.; Barna, A.; Frommlet, F.; Czurda, S.; Konstantin, B.; Alikian, M.; Machova Polakova, K.; Sacha, T.; Richter, J.; Lion, T.; Gabriel, C.

Quantitative analysis of mutant subclones in chronic myeloid leukemia: comparison of different methodological approaches

[rok vydání 2016, impact factor 3.257 ]

[13]

Machová Poláková, K.; Polívková, V.; Rulcová, J.; Klamová, H.; Jurček, T.; Dvořáková, D.; Žáčková, D.; Pospíšil, Z.; Mayer, J.; Moravcová, J.

Constant BCR-ABL transcript level less than or equal 0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis

[rok vydání 2009, impact factor 3.198]

[14]

Machova Polakova, K.; Kulvait, V.; Benesova, A.; Linhartova, J.; Klamova, H.; Jaruskova, M.; de Benedittis, C.; Haferlach, T.; Baccarani, M.; Martinelli, G.; Stopka, T.; Ernst, T.; Hochhaus, A.; Kohlmann, A.; Soverini, S.

Next-generation deep sequencing improves detection of BCR-ABL1 kinase domain mutations emerging under tyrosine kinase inhibitor treatment of chronic myeloid leukemia patients in chronic phase

[rok vydání 2014, impact factor 3.141 ]

[15]

Racil, Z.; Razga, F.; Klamova, H.; Voglova, J.; Belohlavkova, P.; Malaskova, L.; Potesil, D.; Muzik, J.; Zackova, D.; Machova Polakova, K.; Zdrahal, Z.; Malakova, J.; Suttnar, J.; Dyr, J.; Mayer, J.

No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

[rok vydání 2013, impact factor 3.084 ]

[16]

Racil, Z.; Razga, F.; Klamova, H.; Voglova, J.; Belohlavkova, P.; Malaskova, L.; Potesil, D.; Muzik, J.; Zackova, D.; Polakova, K.M.; Zdrahal, Z.; Malakova, J.; Suttnar, J.; Dyr, J.; Mayer, J.

Erratum: No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia

[rok vydání 2015, impact factor 3.084 ]

[17]

Polivkova, V.; Rohon, P.; Klamova, H.; Cerna, O.; Divoka, M.; Curik, N.; Zach, J.; Novak, M.; Marinov, I.; Soverini, S.; Faber, E.; Machova Polakova, K.

Interferon-alpha revisited: individualized treatment management eased the selective pressure of tyrosine kinase inhibitors on BCR-ABL1 mutations resulting in a molecular response in high-risk CML patients

[rok vydání 2016, impact factor 3.057 ]

[18]

Zackova, D.; Klamova, H.; Muzik, J.; Cmunt, E.; Racil, Z.; Machova Polakova, K.; Dvorakova, D.; Jurcek, T.; Razga, F.; Cetkovsky, P.; Dusek, L.; Mayer, J.

Efficacy and tolerance of dasatinib after imatinib failure or intolerance for chronic myeloid leukemia patients treated in three different hospitals compare well with results achievable in formal clinical trials

[rok vydání 2013, impact factor 2.605 ]

[19]

Racil, Z.; Razga, F.; Machova Polakova, K.; Buresova, K.; Polivkova, V.; Dvorakova, D.; Zackova, D.; Klamova, H.; Cetkovsky, P.; Mayer, J.

Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia : the role of different cell types

[rok vydání 2011, impact factor 2.580]

[20]

Toman, O.; Kabickova, T.; Vit, O.; Fiser, R.; Machova Polakova, K.; Zach, J.; Linhartova, J.; Vyoral, D.; Petrak, J.

Proteomic analysis of imatinib-resistant CML-T1 cells reveals calcium homeostasis as a potential therapeutic target

[rok vydání 2016, impact factor 2.486 ]

Neimpaktované publikace

[1]

Jarošová, M.; Moravcová, J.; Machová Poláková, K.

Cytogenetika a molekulární genetika

[rok vydání 2010]